# A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

> **NCT06013995** · PHASE1 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 44 (estimated)

## Conditions studied

- Lupus

## Interventions

- **DRUG:** BMS-986326
- **OTHER:** Placebo for BMS-986326

## Key facts

- **NCT ID:** NCT06013995
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2026-04-08
- **Final completion:** 2026-04-08
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06013995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06013995, "A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06013995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*